1. Home
  2. KRYS vs IESC Comparison

KRYS vs IESC Comparison

Compare KRYS & IESC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • KRYS
  • IESC
  • Stock Information
  • Founded
  • KRYS 2015
  • IESC 1997
  • Country
  • KRYS United States
  • IESC United States
  • Employees
  • KRYS N/A
  • IESC N/A
  • Industry
  • KRYS Biotechnology: Biological Products (No Diagnostic Substances)
  • IESC Engineering & Construction
  • Sector
  • KRYS Health Care
  • IESC Industrials
  • Exchange
  • KRYS Nasdaq
  • IESC Nasdaq
  • Market Cap
  • KRYS 4.5B
  • IESC 5.4B
  • IPO Year
  • KRYS 2017
  • IESC 1998
  • Fundamental
  • Price
  • KRYS $148.39
  • IESC $256.69
  • Analyst Decision
  • KRYS Strong Buy
  • IESC
  • Analyst Count
  • KRYS 7
  • IESC 0
  • Target Price
  • KRYS $206.67
  • IESC N/A
  • AVG Volume (30 Days)
  • KRYS 292.3K
  • IESC 169.5K
  • Earning Date
  • KRYS 02-24-2025
  • IESC 01-31-2025
  • Dividend Yield
  • KRYS N/A
  • IESC N/A
  • EPS Growth
  • KRYS N/A
  • IESC 117.84
  • EPS
  • KRYS 1.77
  • IESC 9.89
  • Revenue
  • KRYS $241,519,000.00
  • IESC $2,884,358,000.00
  • Revenue This Year
  • KRYS $485.65
  • IESC N/A
  • Revenue Next Year
  • KRYS $58.64
  • IESC N/A
  • P/E Ratio
  • KRYS $83.69
  • IESC $25.95
  • Revenue Growth
  • KRYS 2722.80
  • IESC 21.33
  • 52 Week Low
  • KRYS $107.50
  • IESC $80.86
  • 52 Week High
  • KRYS $219.34
  • IESC $320.08
  • Technical
  • Relative Strength Index (RSI)
  • KRYS 37.81
  • IESC 60.06
  • Support Level
  • KRYS $141.72
  • IESC $213.00
  • Resistance Level
  • KRYS $152.94
  • IESC $224.40
  • Average True Range (ATR)
  • KRYS 5.22
  • IESC 12.12
  • MACD
  • KRYS -0.42
  • IESC 6.14
  • Stochastic Oscillator
  • KRYS 33.00
  • IESC 91.98

About KRYS Krystal Biotech Inc.

Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.

About IESC IES Holdings Inc.

IES Holdings Inc owns and manages subsidiaries that design and installs integrated electrical and technology systems and provide infrastructure products and services. It has four business segments; Communications, Residential, Infrastructure Solutions, and Commercial & Industrial. The majority of the revenue for the company is generated from its Residential segment in which the company provides electrical installation services for single-family housing and multi-family apartment complexes, as well as heating, ventilation, and air conditioning (HVAC) and plumbing installation services. This segment also provides services for installing residential solar power, both for new construction and existing residences.

Share on Social Networks: